



Model List of Essential Medicines

Apixaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

Dabigatran

Section	Indications
Medicines affecting coagulation Oral > Solid: 110 mg; 150 mg	Venous thromboembolism Other specified atrial fibrillation

Dalteparin

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism

Desmopressin

Section	Indications
Medicines affecting coagulation Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate) Local > Nasal > Spray: 10 µg per dose (acetate)	Haemophilia A Von Willebrand disease

Edoxaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

Enoxaparin

Section	Indications
<p>Medicines affecting coagulation</p> <p>Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule</p>	<p>Acute ischaemic heart disease</p> <p>Venous thromboembolism</p>

Heparin sodium

Section	Indications
<p>Medicines affecting coagulation</p> <p>Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule; 20000 IU per mL in 1 mL ampoule; 5000 IU per mL in 1 mL ampoule</p>	<p>Acute ischaemic heart disease</p> <p>Unstable angina</p> <p>Venous thromboembolism</p>

Nadroparin

Section	Indications
<p>Medicines affecting coagulation</p>	<p>Therapeutic equivalent to enoxaparin for</p> <p>Acute ischaemic heart disease</p> <p>Therapeutic equivalent to enoxaparin for</p> <p>Venous thromboembolism</p>

Phytomenadione

Section	Indications
<p>Medicines affecting coagulation</p> <p>Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule</p> <p>Oral > Solid: 10 mg tablet</p>	<p>Haemorrhagic disorder due to other specified circulating anticoagulants</p> <p>Haemorrhagic or haematological disorders of fetus or newborn</p>

Protamine sulfate

Section	Indications
<p>Medicines affecting coagulation</p> <p>Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule</p>	<p>Haemorrhagic disorder due to other specified circulating anticoagulants</p>

Rivaroxaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

Tranexamic acid

Section	Indications
Medicines affecting coagulation Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Haemorrhage, not elsewhere classified

Warfarin

Section	Indications
Medicines affecting coagulation Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)	Other specified diseases of arteries or arterioles Cerebral ischaemic stroke due to embolic occlusion Venous thromboembolism Atrial fibrillation